Trial · NCT06662227
Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors
NCT06662227, Early phase 1, Suspended, Wondercel Biotech (ShenZhen)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors. Trials, record NCT06662227. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06662227
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors
- NCT number
- NCT06662227
- Status
- Suspended
- Phases
- Early phase 1
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Wondercel Biotech (ShenZhen)
- Conditions
- B Cell Lymphoma, B Cell Leukemia, B Cell Malignancy
- Interventions
- Single dose injection of certain dose of UWD-19, MMF Immunosuppression
- First posted
- 2024-10-28
- Last updated
- 2026-05-07
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum Tolerated Dose (MTD) | [Time Frame: Within the first month post-infusion.] | The highest dose of UWD-19 CAR-T cells that can be administered without causing unacceptable side effects, measured during the dose escalation phase. |
| Primary | Dose-Limiting Toxicities (DLT) | [Time Frame: Within the first month post-infusion.] | The incidence of treatment-related toxicities that prevent further dose escalation. |
| Primary | Treatment-Emergent Adverse Events (TEAE) | [Time Frame: From the administration of UWD-19 CAR-T cells through six months post-infusion] | The frequency and severity of adverse events that arise following the administration of UWD-19-CAR-T cells. |
| Secondary | Objective Response Rate (ORR) | [Time Frame: Measured at 3 and 6 months after treatment.] | The proportion of patients with a measurable reduction in tumor size (complete or partial response) following UWD-19 CAR-T therapy. |
| Secondary | Progression-Free Survival (PFS) | [Time Frame: From the start of treatment up to 5 years.] | The length of time during and after treatment that the patient lives without disease progression. |
| Secondary | Overall Survival (OS) | [Time Frame: From the start of treatment up to maximum follow-up period of five years.] | The duration from the start of treatment to the time of death from any cause. |
| Secondary | Duration of Response (DOR) | [Time Frame: From the administration of UWD-19 CAR-T cells to a maximum follow-up period of five years.] | The time from initial tumor response (CR or PR) to disease progression or relapse or any cause of death. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06662227
GET https://conductscience.org/api/trials/v1/NCT06662227/registered